Johnson & Johnson (JNJ) EBIAT (2009 - 2026)
Johnson & Johnson recorded quarterly EBIAT of $5.2 billion in Q1 2026, up 2.33% quarter-over-quarter from $5.1 billion in Q4 2025, and down 52.4% year-over-year from $11.0 billion in Q1 2025.
Johnson & Johnson's EBIAT history runs 18 years deep, the most recent figure standing at $5.2 billion for Q1 2026.
- In Q1 2026, EBIAT fell 52.4% year-over-year to $5.2 billion; the TTM figure through Mar 2026 stood at $21.0 billion (down 3.53% YoY), while the FY2025 annual figure was $26.8 billion, up 90.56% from the prior year.
- EBIAT came in at $5.2 billion for Q1 2026 at Johnson & Johnson, up from $5.1 billion in the prior quarter.
- In the past five years, EBIAT ranged from a high of $11.0 billion in Q1 2025 to a low of -$491.0 million in Q2 2023.
- A 5-year average of $4.5 billion and a median of $4.5 billion in 2022 frame the typical range for EBIAT.
- Across the five-year window, EBIAT sank 110.74% in 2023 and soared 762.93% in 2024, its largest moves.
- Johnson & Johnson's EBIAT stood at $4.5 billion in 2022, then decreased by 9.17% to $4.0 billion in 2023, then dropped by 15.26% to $3.4 billion in 2024, then surged by 49.11% to $5.1 billion in 2025, then increased by 2.33% to $5.2 billion in 2026.
- According to Business Quant data, EBIAT over the past three periods registered $5.2 billion, $5.1 billion, and $5.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -4.24 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 5.24 Bn |
| Dec 28, 2025 | 5.12 Bn |
| Sep 28, 2025 | 5.15 Bn |
| Jun 29, 2025 | 5.54 Bn |
| Mar 30, 2025 | 11.00 Bn |
| Dec 29, 2024 | 3.43 Bn |
| Sep 29, 2024 | 2.69 Bn |
| Jun 30, 2024 | 4.69 Bn |
| Mar 31, 2024 | 3.26 Bn |
| Dec 31, 2023 | 4.05 Bn |
| Oct 1, 2023 | 4.31 Bn |
| Jul 2, 2023 | 5.38 Bn |
| Apr 2, 2023 | -491.00 Mn |
| Jan 1, 2023 | 3.23 Bn |
| Oct 2, 2022 | 4.46 Bn |
| Jul 3, 2022 | 4.26 Bn |
| Apr 3, 2022 | 4.57 Bn |
| Oct 3, 2021 | 3.67 Bn |
| Jul 4, 2021 | 6.28 Bn |
| Apr 4, 2021 | 6.20 Bn |
| Jan 3, 2021 | 1.74 Bn |
| Sep 27, 2020 | 3.55 Bn |
| Jun 28, 2020 | 3.63 Bn |
| Mar 29, 2020 | 5.80 Bn |
| Dec 29, 2019 | 4.01 Bn |
| Sep 29, 2019 | 1.75 Bn |
| Jun 30, 2019 | 5.61 Bn |
| Mar 31, 2019 | 3.75 Bn |
| Dec 30, 2018 | 3.04 Bn |
| Sep 30, 2018 | 3.93 Bn |
| Jul 1, 2018 | 3.95 Bn |
| Apr 1, 2018 | 4.37 Bn |
| Dec 31, 2017 | -10.71 Bn |
| Oct 1, 2017 | 3.76 Bn |
| Jul 2, 2017 | 3.83 Bn |
| Apr 2, 2017 | 4.42 Bn |
| Jan 1, 2017 | 3.81 Bn |
| Oct 2, 2016 | 4.27 Bn |
| Jul 3, 2016 | 4.00 Bn |
| Apr 3, 2016 | 4.46 Bn |
| Jan 3, 2016 | 3.22 Bn |
| Sep 27, 2015 | 3.36 Bn |
| Jun 28, 2015 | 4.52 Bn |
| Mar 29, 2015 | 4.32 Bn |
| Dec 28, 2014 | 2.52 Bn |
| Sep 28, 2014 | 4.75 Bn |
| Jun 29, 2014 | 4.33 Bn |
| Mar 30, 2014 | 4.73 Bn |
| Dec 29, 2013 | 3.52 Bn |
| Sep 29, 2013 | 2.98 Bn |
| Jun 30, 2013 | 3.83 Bn |
| Mar 31, 2013 | 3.50 Bn |
| Dec 30, 2012 | 2.57 Bn |
| Sep 30, 2012 | 2.97 Bn |
| Jul 1, 2012 | 1.41 Bn |
| Apr 1, 2012 | 3.91 Bn |
| Jan 1, 2012 | 218.00 Mn |
| Oct 2, 2011 | 3.20 Bn |
| Jul 3, 2011 | 2.78 Bn |
| Apr 3, 2011 | 3.48 Bn |
| Jan 2, 2011 | 2.23 Bn |
| Oct 3, 2010 | 3.42 Bn |
| Jul 4, 2010 | 3.45 Bn |
| Apr 4, 2010 | 4.53 Bn |
| Jan 3, 2010 | 2.21 Bn |
| Sep 27, 2009 | 3.35 Bn |
| Jun 28, 2009 | 3.21 Bn |
| Mar 29, 2009 | 3.51 Bn |